Cogent Biosciences, Inc. Long-Term Debt, Maturity, Year Two
Cogent Biosciences, Inc. (COGT) had Long-Term Debt, Maturity, Year Two of $0 as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2025-11-07
- 2025-09-30: Long-Term Debt, Maturity, Year Two $0.00.
- 2025-06-30: Long-Term Debt, Maturity, Year Two $0.00.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |